Drug
Padeliporfin clinical trials
Also written WST11.
Includes 1 study of Padeliporfin potassium.
- studies test it
- 12
- open now
- 0
- in phase 3
- 3
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 12
Steba Biotech S.A. (10) · Memorial Sloan Kettering Cancer Center (2)
Studies
Open first, then newest update. How each study uses padeliporfin is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.CompletedPhase 2Steba Biotech S.A.NCT03315754Written as TOOKAD Soluble 4 mg/kg
- ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudyActive, not recruitingPhase 3Steba Biotech S.A.NCT04620239Written as padeliporfin VTP
- A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble SwallowingActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT03133650Written as WST 11-mediated VTP therapy
- Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)CompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03617003Written as WST11 mediated vascular targeted phototherapy (VTP)
- Safety and Tolerability Study Using WST11 In Patients With Localized Prostate CancerCompletedPhase 1/2Steba Biotech S.A.NCT00946881Written as WST 11 -mediated -VTP
- Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.CompletedPhase 3Steba Biotech S.A.NCT01310894Written as TOOKAD® Soluble
- Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMDTerminatedPhase 2Steba Biotech S.A.NCT01021956Written as STAKEL
- Study of WST11 in Patients With Localized Prostate CancerCompletedPhase 2Steba Biotech S.A.NCT00707356Written as WST11
- Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate CancerCompletedPhase 3Steba Biotech S.A.NCT01875393Written as TOOKAD® Soluble
- Study Using WST11 in Patients With Non-Resectable or Inoperable CholangiocarcinomaTerminatedPhase 2Steba Biotech S.A.NCT00975039Written as WST11
- Study Using WST11 in Patients With Localized Prostate CancerCompletedPhase 2Steba Biotech S.A.NCT00975429Written as WST11
- Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung CancerTerminatedPhase 2Steba Biotech S.A.NCT00974662Written as WST11
Codes
What other systems call padeliporfin · ClinicalTrials.gg INT004810
- MeSH (NLM) C503696padeliporfinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) EEO29FZT86PADELIPORFINConfirmed FDA, NLM, Wikidata
- Wikidata Q27277134padeliporfinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78481PadeliporfinOne source FDA
- DrugBank DB15575One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C503696 | padeliporfin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | EEO29FZT86 | PADELIPORFIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27277134 | padeliporfin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78481 | Padeliporfin | One source FDA |
| DrugBank | DB15575 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.